依达拉奉应用于进展性缺血性脑卒中患者的疗效及对血浆红细胞生成素的影响

张久德1，王书民2

（1.西安市华山中心医院神经内科，陕西 西安，710043；2.西安市第三医院药剂科，陕西 西安，710082）

浏览次数：57次 下载次数：498次

摘要：

目的 探讨依达拉奉应用于进展性缺血性脑卒中患者的疗效观察及对血浆红细胞生成素（EPO）的影响。方法 选择我 院收治的进展性缺血性脑卒中患者72例，以随机数字表将其分为研究组与对照组，每组36例。在常规对症支持治疗的基础 上，研究组静滴依达拉奉治疗，对照组应用等容积的安慰剂生理盐水静滴。观察两组患者的临床疗效、治疗前、后血浆EPO水平及药物不良反应。结果 研究组患者的临床治疗总有效率为88.89%，显著高于对照组的69.44%（P<0.05）。两组患者治疗前血浆EPO水平比较，差异无统计学意义（P>0.05）；研究组患者治疗14 d 时血浆EPO水平显著高于对照组与治疗前（P< 0.05）。两组患者治疗期间均未发现明显的药物不良反应。结论 依达拉奉应用于进展性缺血性脑卒中患者中疗效显著，可有效改善患者的神经功能状态，提高血浆EPO水平，适于临床推广。

关键词：依达拉奉；进展性缺血性脑卒中；血浆红细胞生成素

中图分类号：R743.3文献标志码：A文章编号：2096-1413(2017)28-0043-02

Efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin
ZHANG Jiu-de 1, WANG Shu-min 2
(1.Department of Neurology, Huashan Central Hospital, Xi``an 710043; 2. Department of Pharmacy, Xi``an No.3 Hospital, Xi``an 710082, China)

ABSTRACT: Objective To investigate the efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin (EPO). Methods A total of 72 cases of patients with progressive ischemic stroke in our hospital were divided into study group and the control group by random number table, with 36 cases in each group. On the basis of conventional symptomatic supportive therapy, the study group was treated with intravenous infusion of edaravone, and the control group received a constant volume of placebo saline intravenous infusion. The clinical efficacy, plasma EPO level and adverse drug reactions of the two group were observed before and after treatment. Results The total effective rate of the study group was 88.89%, which was significantly higher than 69.44% of the control group(P<0.05). There was no significant difference in plasma EPO levels between the two groups before treatment (P>0.05). The level of plasma EPO at 14 d in the study group was significantly higher than that in the control group and before treatment (P<0.05). There was no obvious adverse drug reactions in the two groups during the treatment. Conclusion Edaravone is effective in the treatment of patients with progressive ischemic stroke. It can effectively improve the neurological status and the level of plasma EPO, which is suitable for clinical promotion.
KEYWORDS: edaravone; progressive ischemic stroke; plasma erythropoietin

参考文献：
[1] 王晓周,莫丽亚,李晓凤.依达拉奉治疗老年脑卒中后迟发性癫痫的疗效[J].中国老年学杂志,2013,33(2):408-409.
[2] 李涛,黄维.依达拉奉联合舒血宁治疗脑梗死的系统评价[J].华西医学,2014,29(3):478-482.
[3] 王飞雪,马克信,王大伟,等.基于血管神经单元、网络药理学中医抗缺血性脑卒中系列药物研发新思路[J].中国中医基础医学杂志,2014,20(5):676-677.
[4] 马海燕.骨髓间充质干细胞移植联合依达拉奉抑制脑梗死后的神经元凋亡[J].中国组织工程研究,2014,18(10):1615-1620.
[5] 刘艳,严爱龙,胡亚丹.依达拉奉治疗急性脑梗死的疗效及安全性研究[J].神经损伤与功能重建,2014,9(2):167.
[6] 吕燕华,曹亦宾,郭红梅,等.依达拉奉治疗老年进展性缺血性脑卒中的临床疗效及机制[J].中国老年学杂志,2014,34(15):4178-4179.
[7]李婛,邹东华,雷斌,等.脑源性神经营养因子与脑卒中的研究进展 [J].中国老年学杂志,2014,34(13):3795-3797.
[8] 佘君慧,林达伟.依达拉奉联合丹参多酚酸盐治疗急性脑梗死的临床研究[J].北京医学,2014,36(6):512-513.
[9] 闫海燕,郗红艳,王红梅,等.丁苯酞治疗大面积脑梗死的临床应用研究[J].中国生化药物杂志,2014,34(3):127-129.
[10] 胡晓,瞿浩,顾然,等.急性缺血性脑血管病静脉溶栓前后并用其他药物对疗效影响的研究进展[J].中风与神经疾病杂志,2014,31(9):863-864.
[11] 华梅,胡仁琳,李鸣.依达拉奉静滴对脑梗死患者血清HMGB1 及 S100β水平的影响[J].山东医药,2014,54(42):67-69.